(Weber Shandwick Worldwide) The Myelodysplastic Syndromes Foundation supports the decision by the US Food and Drug Administration to extend the label for vidaza to include data from the AZA-001 clinical trial.

Results from the trial found that azacitidine is the only agent which has been shown to extend survival in MDS patients.